Kristie M. Grebe

The Navigator (Portugal) — Portugal

Immunology and Microbiology · Life Sciences

14h-index1.1kcitations34works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(7), Immune Cell Function and Interaction(6), Microscopic Colitis(5), Influenza Virus Research Studies(4), Celiac Disease Research and Management(4)

Publications34 total

62 A First-in-Human Phase 1a Randomized, Double-Blind, Single-Ascending Dose Study of NAV-240, an anti-OX40L/TNF-α Bispecific Antibody, in Healthy Volunteers
Journal of Investigative Dermatology·2025
468 ASSESSMENT OF KAN-101 IN CED AND IMMUNE TOLERANCE (ACED-IT) STUDY, PH1B DATA WITH HIGHER DOSE LEVELS OF KAN-101, A NOVEL IMMUNE TOLERANCE THERAPY FOR CELIAC DISEASE
Gastroenterology·2024
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial
˜The œLancet. Gastroenterology & hepatology·2023· 54 cited
1024 PHARMACODYNAMIC DEMONSTRATION OF IMMUNOLOGICAL TOLERANCE INDUCED BY KAN-101, A NOVEL LIVER-TARGETED THERAPY FOR CELIAC DISEASE, PERSISTS FOLLOWING DRUG CLEARANCE
Gastroenterology·2023
579: SAFETY, TOLERABILITY AND PHARMACODYNAMIC ASSESSMENT OF KAN-101, A NOVEL LIVER-TARGETED THERAPY TO INDUCE IMMUNOLOGICAL TOLERANCE TO GLIADIN IN CELIAC DISEASE
Gastroenterology·2022· 4 cited
Tu1763 – Systemic and Tissue Modulation of Il-23 Pathway Biomarkers in a Phase 2 Study of Risankizumab in Patients with Crohn's Disease
Gastroenterology·2019
1024 Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates
Journal of Investigative Dermatology·2019· 5 cited
Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings
Journal of Allergy and Clinical Immunology·2019· 7 citedOpen Access
P315 Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease
Journal of Crohn s and Colitis·2019Open Access
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab
Journal of Allergy and Clinical Immunology·2018· 68 citedOpen Access
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn’s Disease: Results From a Randomised Phase II Biopsy Sub-study
Journal of Crohn s and Colitis·2018· 44 citedOpen Access
350 RNA-seq genomic analysis demonstrated the molecular efficacy of Risankizumab in a moderate-to-severe plaque psoriasis phase 2 clinical study
Journal of Investigative Dermatology·2018· 4 cited
Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus
Lupus·2017· 32 cited
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
Annals of the Rheumatic Diseases·2016
Venetoclax (ABT-199), a potent and selective BCL-2 inhibitor, is efficacious in NZB/WF1 mouse model of lupus nephritis and reduces human lymphocyte lifespan in vitro (BA4P.127)
The Journal of Immunology·2015· 2 cited
AB0032 Bcl-2:Bim Ratios in Human Peripheral Blood Mononuclear Cell Subsets May Predict Sensitivity to BCL-2 Inhibition
Annals of the Rheumatic Diseases·2014
Lack of adalimumab's complement dependent cytotoxicity on human cells expressing complement regulatory proteins
Journal of Translational Medicine·2010· 2 citedOpen Access
Unexpected Role for the Immunoproteasome Subunit LMP2 in Antiviral Humoral and Innate Immune Responses
The Journal of Immunology·2010· 99 citedOpen Access
Assessment of Adalimumab's Complement Activity with Human Cells Expressing Complement Regulatory Proteins
Clinical Immunology·2010
Cutting Edge: Sympathetic Nervous System Increases Proinflammatory Cytokines and Exacerbates Influenza A Virus Pathogenesis
The Journal of Immunology·2009· 127 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jack R. Bennink(6), Heather D. Hickman(6), Jonathan W. Yewdell(5), Terry A. Potter(4), J. Wade Davis(4), Sally A. Litherland(4), Michael Clare‐Salzler(4), Joseph A. Murray(3), Dina Wassaf(3), Kaela E. Goldstein(3), Stephan Kontos(3), Azucena Salas(3), Kori Wallace(3), Julián Panés(3), Kazuyo Takeda(2), Alan C. Embry(2), Kari R. Irvine(2), Sudha Visvanathan(2), Patrick Baum(2), Richard Vinisko(2)